Evidence map›Paper›PMID 40769518›Full record

ReviewThe clinical respiratory journal2025

Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease.

Agata Anna Lewandowska, Dorota Waśniowska, Cezary Rybacki, Michał Graczyk, Ola Duszyńska, Helena Mirus-Arabik, Aleksandra Gaczkowska, Małgorzata Kołodziej

Abstract readReview
In one paragraph

Review in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Agata Anna LewandowskaClinical Department of Pulmonology, Allergology and Pulmonary Oncology, 10th Military Clinical Hospital With Polyclinic in Bydgoszcz, Bydgoszcz, Poland.ORCID https://orcid.org/0000-0002-0966-8467
Dorota WaśniowskaClinical Department of Pulmonology, Allergology and Pulmonary Oncology, 10th Military Clinical Hospital With Polyclinic in Bydgoszcz, Bydgoszcz, Poland.ORCID https://orcid.org/0009-0003-9338-4858
Cezary RybackiClinical Department of Pulmonology, Allergology and Pulmonary Oncology, 10th Military Clinical Hospital With Polyclinic in Bydgoszcz, Bydgoszcz, Poland.ORCID https://orcid.org/0009-0002-6840-9323
Michał GraczykDepartment of Palliative Care, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland.ORCID https://orcid.org/0000-0002-9121-6274
Ola DuszyńskaClinical Department of Pulmonology, Allergology and Pulmonary Oncology, 10th Military Clinical Hospital With Polyclinic in Bydgoszcz, Bydgoszcz, Poland.
Helena Mirus-ArabikClinical Department of Pulmonology, Allergology and Pulmonary Oncology, 10th Military Clinical Hospital With Polyclinic in Bydgoszcz, Bydgoszcz, Poland.ORCID https://orcid.org/0000-0001-9941-2619
Aleksandra GaczkowskaClinical Department of Pulmonology, Allergology and Pulmonary Oncology, 10th Military Clinical Hospital With Polyclinic in Bydgoszcz, Bydgoszcz, Poland.
Małgorzata KołodziejClinical Department of Oncology, Oncology Center of Prof. Franciszek Lukaszczyk in Bydgoszcz, Poland.ORCID https://orcid.org/0009-0001-4360-1039

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial lung disease (ILD) associated with connective tissue disease (CTD) is a challenging entity burdened with multiple risk factors and undesirable events. ILD can occur at any time and progress regardless of the underlying disease activity. Apart from the established difficulties in choosing an appropriate treatment strategy for both pulmonary and extrapulmonary involvement, such patients require a holistic and multidisciplinary approach. In an attempt to emphasize the significance of the problem and suggest potential research directions, the authors present four potentially most important and often misdiagnosed complications of the CTD-associated ILD, in the form of acute exacerbation, drug-induced pulmonary toxicity, nonspecific infection, and tuberculosis. Similar clinical manifestations of the patient's progressive deterioration, as well as the complex etiology of pulmonary involvement, raise controversies and force difficult therapeutic decisions. High morbidity and mortality among patients with progressive CTD-associated ILDs necessitate further research in an attempt to enhance the treatment management in each CTD and improve the patients' quality of life.

Indexed as

Connective Tissue DiseasesLung Diseases, InterstitialDisease ProgressionHumansQuality of LifeRisk Factorsconnective tissue diseasedrug‐inducedexacerbationinfectioninterstitial lung diseaserheumatictuberculosis

Identifiers

PMID40769518
PMCPMC12328024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.